Table 4.
Imiquimod Therapy
| Stage | Patients | Length of Treatment |
Frequency | Response | Side Effects | Recurrence | F/U | |
|---|---|---|---|---|---|---|---|---|
| Suchin, 2002 [29] | IA | 1 | 4 months | Daily | CR | Vesicles, erythema, erosions, pruritus |
NR | 4 months |
| Dummer, 2003 [47] | NR | 1 | 8 weeks | Daily | CR | Ulceration | No | 12 months |
| Chong, 2004 [48] | IB | 3 | NR | Daily | NR | Mild Irritation | NR | 32 weeks |
| Deeths, 2005 [30] | IA to IIB | 6 | 12 weeks | 1–3 times per week |
3 of 6 had CR, 1 of 6 had PR, 2 of 6 had minimal or no response |
Erythema, irritation, erosion and ulceration |
NR | 16 weeks to 2 years |
| Chiam, 2006 [33] | IA | 1 | 4.5 months | Every other day | CCR | Pain, ulceration | No | 6 mo |
| Ardigo, 2006 [32] | IA | 1 | 24 weeks | 5x/week | CR | Erythema, Edema | No | 6 mo |
| Coors, 2006 [34] | IA to IB | 4 | 8–24 weeks | 3x/week | 50% CCR | Erythema, papules, pruritus |
NR | 6 to 45months |
| Martinez-Gonzalez, 2008 [31] |
IA to IIB | 4 | 3–14 months | 3x/week | 100% CR | Localized inflammation |
Yes | NR |
CR- Complete Response, CCR-Clinical Complete Response (no histologic confirmation), PR- Parital Response, NR- Not Reported.